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Diagnosis and Management
of Lymphatic Vascular Disease
Stanley G. Rockson, MD
Stanford, California
The lymphatic vasculature is comprised of a network of vessels that is essential both to fluid homeostasis and
to the mediation of regional immune responses. In health, the lymphatic vasculature possesses the requisite
transport capacity to accommodate the fluid load placed upon it. The most readily recognizable attribute of lym-
phatic vascular incompetence is the presence of the characteristic swelling of tissues, called lymphedema,
which arises as a consequence of insufficient lymph transport. The diagnosis of lymphatic vascular disease re-
lies heavily upon the physical examination. If the diagnosis remains in question, the presence of lymphatic vas-
cular insufficiency can be ascertained through imaging, including indirect radionuclide lymphoscintigraphy. Be-
yond lymphoscintigraphy, clinically-relevant imaging modalities include magnetic resonance imaging and
computerized axial tomography. The state-of-the-art therapeutic approach to lymphatic edema relies upon phys-
iotherapeutic techniques. Complex decongestive physiotherapy is an empirically-derived, effective, multicompo-
nent technique designed to reduce limb volume and maintain the health of the skin and supporting structures.
The application of pharmacological therapies has been notably absent from the management strategies for lym-
phatic vascular insufficiency states. In general, drug-based approaches have been controversial at best. Surgical
approaches to improve lymphatic flow through vascular reanastomosis have been, in large part, unsuccessful,
but controlled liposuction affords lasting benefit in selected patients. In the future, specifically engineered molecu-
lar therapeutics may be designed to facilitate the controlled regrowth of damaged, dysfunctional, or obliterated lym-
phatic vasculature in order to circumvent or mitigate the vascular insufficiency that leads to edema and tissue
destruction. (J Am Coll Cardiol 2008;52:799–806) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.005v
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ahe lymphatic vasculature, an integral component of the
ammalian circulation, is comprised of a network of vessels
hat is essential both to fluid homeostasis and to the
ediation of regional immune responses (1). This vascula-
ure consists of a series of conduits to interconnect the
ody’s interstitial spaces with the lymphoid organs (thymus,
pleen, and lymph nodes), and the central circulation,
espectively. The vessels are structurally and functionally
pecialized to mediate the collection and homeostatic reg-
lation of the protein-enriched fluid that is excluded from
he venous end of the blood capillary (2). The distinctive
tructural attributes of the lymphatic capillary network
upport this vital physiological task: in contrast to the blood
irculation, the endothelial monolayers of the lymphatic
apillaries display loose junctions that facilitate the entry of
uid, macromolecules, and cells (3). In parallel to its role in
xtracellular homeostasis, the lymphatic vasculature pro-
otes the traffic of immune cells and fosters lymphocyte
opulation growth (4).
rom the Stanford Center for Lymphatic and Venous Disorders, Division of Cardio-
ascular Medicine, Stanford University School of Medicine, Stanford, California.s
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ccepted June 3, 2008.Unlike the circulation of body fluids through the blood
asculature, lymphatic flow occurs through a low pressure
ystem (5). Interstitial fluid gains entry through the initial
ymphatics that abut the interstitial space. These structures
oalesce into conduits of increasing caliber that, ultimately,
ecome invested with a smooth muscle coat and possess the
apacity for rhythmic contractility; these collecting vessels
ventually drain their fluid content (lymph) into the central
asculature, chiefly through the thoracic duct (2).
ymphedema: The Functional
onsequence of Impaired Lymphatic Function
broad spectrum of inherited and acquired disease is
haracterized by an impaired ability of the lymphatic vas-
ulature to collect and transport fluid. The ensuing stasis of
ymph flow is associated with blunted regional immune
rafficking, local inflammatory changes, and a heightened
ropensity to infection, often with ensuing organ or tissue
amage (6). The most readily recognizable attribute of
ymphatic vascular incompetence is the presence of the
haracteristic swelling of tissues, called lymphedema, which
rises as a consequence of insufficient lymph transport.
In health, the lymphatic vasculature possesses the requi-ite transport capacity to accommodate the fluid load placed
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lation of fluid within the intersti-
tium that denotes the presence
of lymphedema. Thus, lymph-
edema is the consequence of an
imbalance between the rate of
lymph production (lymphatic load)
and its removal through the lym-
phatic vascular channels (lym-
phatic transport capacity). The
production of lymph can be en-
hanced by increased capillary
permeability, venous hyperten-
sion, or diminished capillary on-
cotic pressure. Accordingly, local
inflammatory responses, venous
hromboembolism, or hypoproteinemia can each, individu-
lly, produce the clinical appearance of lymphedema, even in
he absence of concomitant damage or dysfunction of the
ymphatic vasculature. Conversely, when the lymphatic
asculature is disrupted, malformed, or displays inadequate
unctional responses, the same clinical picture can ensue,
ith the propensity toward increasing interstitial fluid
olume despite a normal rate of interstitial fluid production.
mpairment of lymphatic flow can result from either pri-
ary or acquired (secondary) anomalies of lymphatic trans-
ort. It is conceivable that the binary classification scheme
epresents a spectrum in which there are anatomic and
enetic features that predispose to vascular malfunction or
nsufficient repair; when coupled with a sufficient initiating
timulus (infection; trauma, either iatrogenic or spontane-
us; extrinsic compression; intraluminal tumor invasion),
ymphatic vascular insufficiency of clinical proportions may
merge. In this view, larger magnitudes of acquired lym-
hatic vascular disruption require proportionately smaller
egrees of an intrinsic predisposition to the development of
ymphedema, while in situations of profound anatomic
ymphatic derangement (i.e., congenital lymphedema), no
dditional environmental stress is required to elicit the
unctional consequences of lymphatic vascular insufficiency.
The tissue biology of lymphedema is complex and can be
istinguished from the other pathophysiological mecha-
isms that lead to interstitial edema. In the limbs, persis-
ence of lymphedema predisposes, often inexorably, to
utaneous thickening and hypercellularity (7), progressive
brosis, and pathological increases in the deposition of
ubcutaneous and subfascial adipose tissue (6,8). In addition
o a variable impairment in function of the affected limbs,
hronic discomfort often will accompany the dramatic
hanges in size and structure. Clinically, the presence of
ymphedema markedly affects the quality of life and
elf-perception of the patient, including depression, anx-
ety, and problems with social adjustment (9). Depending
pon pathogenesis and the regional distribution of the
Abbreviations
and Acronyms
CDPT  complex
decongestive physiotherapy
KTS  Klippel-Trenaunay
syndrome
LAM 
lymphangioleiomyomatosis
MLD  manual lymphatic
drainage
VEGF  vascular
endothelial growth factor
VEGFR  vascular
endothelial growth factor
receptorascular defect within the affected individual, variousubjective complaints can accompany lymphatic malfunc-
ion (Table 1).
Structural alterations of the lymphatic vascular conduits
redicate the functional derangements and disease manifes-
ations that ensue (10). With hypoplasia or aplasia of the
ymphatic vessels, especially in the presence of primary
ymphatic valvular insufficiency, the consequence is de-
reased contractility, lymphatic hypertension, and the de-
elopment or exacerbation of valvular incompetence. Oblit-
ration or disruption of lymphatic vessels promotes stasis of
ymph, with the attendant accumulation-retained interstitial
roteins, and glycosaminoglycans.
econdary lymphedema. Acquired (“secondary”) lymph-
dema is the most commonly encountered form of lymphatic
ysfunction; among these, in the U.S., iatrogenic causes
redominate. This pattern reflects the common lymphatic
rauma that is engendered by surgical and radiotherapeutic
nterventions for cancer (11). Within the category of disease
he Clinical Spectrum ofymphati Vascular Disease
Table 1 The Clinical Spectrum ofLymphatic Vascular Disease
Symptom Association
General
Nausea Lymphangioleiomyomatosis
Pulmonary lymphangiectasia
Changes in appetite Noonan syndrome
Prader-Willi syndrome
Weight loss Protein-losing enteropathy
Amenorrhea and infertility Turner syndrome
Delayed puberty Hennekam’s syndrome
Fever Filariasis
Xerophthalmia Turner’s syndrome
Pruritus Aagenaes syndrome
Chest pain Lymphangioleiomyomatosis
Gynecomastia Klinefelter’s syndrome
Respiratory
Hemoptysis Lymphangioleiomyomatosis
Sputum production Lymphangioleiomyomatosis
Dyspnea and wheezing Intestinal lymphangiectasia
Lymphangioleiomyomatosis
Lymphangiomatosis
Gastrointestinal
Dysphagia Noonan syndrome
Emesis Intestinal lymphangiectasia
Noonan syndrome
Hematemesis Blue rubber bleb nevus syndrome
Jaundice Aagenaes syndrome
Bloating Lymphangioleiomyomatosis
Musculoskeletal
Joint or muscle pain Blue rubber bleb nevus syndrome
Noonan syndrome
Back pain Neurofibromatosis
Bony fractures Cystic angiomatosis
Dermatological
Skin lesions Blue rubber bleb nevus syndrome
Maffucci syndromeNeurofibromatosis
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September 2, 2008:799–806 Lymphatic Vascular Diseaseelated to cancer therapeutics, breast cancer-associated
ymphedema of the upper extremity is the most commonly
ncountered problem. Lymph node dissection and adjuvant
adiation therapy independently and synergistically predis-
ose to lymphatic vascular insufficiency (12). The most
ecent estimates suggest that, after axillary intervention,
0% to 30% of breast cancer survivors will experience
linically relevant lymphedema (13,14). Despite recent sur-
ical and radiotherapeutic technical enhancements, lymph-
dema remains problematic (15). Comparable lymphatic
equelae are encountered after interventions for malignant
elanoma and gynecological or urological malignancies
16). Lymphedema can also be acquired from other forms of
ymphatic vascular trauma, including burns and large or
ircumferential wounds to the extremity. Additional causes
f acquired lymphedema include pregnancy, contact derma-
itis, and rheumatoid arthritis. Autoimmune destruction of
he lymphatics has been hypothesized but not directly
emonstrated.
rimary lymphedema. Primary lymphedema is not com-
on, but not rare (17), with prevalence estimates for
ongenital lymphedema that approximate 1:6,000 to 10,000
ive births. Many of the associated syndromes have been
haracterized to possess an autosomal pattern of genetic
ransmission, yet, somewhat inexplicably, there is often a
emale predominance, with female:male ratios estimated to
e between 2.5 and 10:1.
Primary lymphedema comprises a heterogeneous group
f disorders. Among this group of diseases is a broad array
f complex syndromes whose pathogenesis has not, in most
ases, been delineated (Table 1). Among the entities that are
ransmitted in a Mendelian fashion, both recessive and dom-
nant genetic transmission has been described for the familial
auses of lymphedema. Among the former, one encounters
ennekam’s syndrome (18), Prader-Willi syndrome (19), and
agenaes syndrome (20). In general, the recessive and
ender-linked disorders are encountered far less commonly.
ominant transmission characterizes Noonan’s syndrome
21), neurofibromatosis, and Adams-Oliver syndrome (22), a
rofound disorder of vascular development.
It has long been recognized that, for cases of primary
ymphedema that lack accompanying phenotypic alter-
tions, there is often, nevertheless, a familial pattern of
ccurrence. The autosomal dominant form of congenital
amilial lymphedema, often called Milroy disease, was orig-
nally described in 1892 (23). Within the last decade, the
efect has been linked, in many of the families examined, to
missense inactivating mutation in the flt4 locus that
ncodes the vascular endothelial growth factor receptor
VEGFR)-3 (24), suggesting that a heritable disorder of
ymphatic vasculogenesis is responsible for the hypoplastic
ymphatic vasculature and lymphedema that are present at
irth.
Lymphedema-distichiasis represents an additional autoso-
al dominant cause of familial lymphedema. The syndromes characterized by the pubertal or post-pubertal onset of a lore distally distributed form of lymphedema in association
ith the presence of a supplementary row of eyelashes
distichiasis) that arise from the Meibomian glands. This
isorder, among an array of primary lymphedema pheno-
ypes, has been linked to truncating mutations in the
orkhead-related transcription factor, FOXC2 (25).
A third, more unusual, form of congenital lymphedema,
ypotrichosis-lymphedema-telangiectasia, has been linked to
utations in the transcription factor gene SOX18 (26).
utosomal dominant and recessive patterns of transmission
ave both been described. It is likely that the SOX18
ranscription factor plays a role in the development and/or
aintenance of lymphatic vessels, but the exact nature of
his role remains to be elucidated.
he Clinical Spectrum
f Lymphatic Vascular Disease
eyond lymphedema, there is a broad spectrum of human
athology that has the capacity to impair the functional
ntegrity of the lymphatic vasculature (Table 1) (27).
Lymphangioma is a lesion of embryological development
hat is usually present at birth and is normally detected
linically within the first 2 years of life (28). When lesions
re multiple or widespread, the term lymphangiomatosis is
pplied. The lesions likely arise from the failure of proper
nastomosis during vascular development (28). Lym-
hangiomatous lesions are classified by size and depth of
ormation.
Complex vascular malformations arise as a consequence
f abnormal development or through insult to the blood
ascular and lymphatic vascular systems during embryogen-
sis. Representative diagnostic entities include cystic angio-
atosis (29), Maffucci syndrome (30), Proteus syndrome (31),
nd blue rubber bleb nevus syndrome. Gorham’s disease results
rom the uncontrolled growth of nonmalignant vascular
hannels that lead to lysis of the affected bone. The
ondition is associated with angiomatosis of blood and
ymphatic vessels; chylous pericardial and pleural effusions
re associated with this condition, thought to represent a
isorder of lymphangiogenesis (32).
Klippel-Trenaunay syndrome (KTS) reflects a constellation
f vascular malformations, including capillary, venous, and
ymphatic components, accompanied by the hypertrophy of
one and soft tissue (33). Most commonly, KTS manifests
n a single extremity, but it can affect multiple limbs or the
ntire body. Some KTS patients display mutations in the
GFQ gene, an angiogenic growth factor. These mutations
re either chromosomal translocations or point mutations,
nd both tend to enhance the effect of the protein (34).
Patients with protein-losing enteropathy develop hypopro-
einemia as a consequence of excessive protein loss into the
astrointestinal lumen. In this condition, obstruction of
ymphatic vasculature yields increased hydrostatic pressure
hroughout the gastrointestinal lymphatics, resulting in
ymph stasis. Protein loss is nonselective, in contradistinc-
t
l
O
p
i
p
l
t
p
f
a
o
s
t
t
w
t
l
t
c
m
t
c
D
T
t
i
m
i
p
“
e
c
c
c
c
u
f
l
i
a
l
d
b
c
s
d
i
l
r
n
“
t
i
h
m
p
m
c
t
w
c
m
r
f
b
c
f
t
e
fi
s
i
802 Rockson JACC Vol. 52, No. 10, 2008
Lymphatic Vascular Disease September 2, 2008:799–806ion to glomerular diseases, where loss is size dependent. If
oss of albumin exceeds its rate of synthesis, edema develops.
ther clinical manifestations include ascites and pleural and
ericardial effusions.
Intestinal lymphangiectasia is a rare condition character-
zed by severe edema, thickening of the small-bowel wall,
rotein-losing enteropathy, ascites, and pleural effusion. If
ymphatic fluid and proteins are lost into the gastrointestinal
ract, patients present with generalized edema due to hy-
oproteinemia. The condition may be primary, resulting
rom a congenital lymphatic vascular disorder, or secondary,
s a consequence of inflammatory or neoplastic involvement
f the lymphatic system.
Lymphangioleiomyomatosis (LAM) is characterized by the
pread of abnormal smooth muscle cells (LAM cells)
hrough the axial lymphatics and the pulmonary intersti-
ium, thereby creating cystic destruction of the lung along
ith lymphatic wall thickening (35). LAM is also charac-
erized by the presence of pulmonary cysts and angiomyo-
ipomas. LAM is an extremely rare disease, found in less
han 1 in a million individuals. It affects mainly women of
hildbearing age. The clinical presentation is typically pul-
onary, featuring primarily cough, hemoptysis, pneumo-
horax, progressive dyspnea, chylous pleural effusions, and
hyloptysis (35).
iagnosis
he diagnosis of lymphatic vascular disease relies heavily on
he physical examination. Lymphedema, even when super-
mposed upon a more complex vascular presentation, is
ost often readily identified by its physical characteristics,
ncluding edema, peau d’orange, cutaneous fibrosis, and
ositive “Stemmer sign” (the inability of the examiner to
tent” the skin at the base of the digits in the involved
xtremity) (36). While pitting edema may be absent, it is a
ommon misconception that the presence of pitting pre-
ludes a lymphatic origin of limb swelling. However, in all
ases, the hallmark of lymphedema is the presence of
utaneous and subcutaneous thickening (Fig. 1), which
niquely identifies the lymphatic pathogenesis of edema
ormation.
If the diagnosis remains in question, the presence of
ymphatic vascular insufficiency can be ascertained through
maging. Direct contrast lymphography has largely been
bandoned, in favor of the use of indirect radionuclide
ymphoscintigraphy (10,37). The procedure requires intra-
ermal or subcutaneous injection of an appropriate radiola-
eled tracer (99mTc-antimony sulfide colloid, 99mTc-sulfur
olloid, 99mTc-albumin colloid, or 99mTc-labeled human
erum albumin). Criteria for the diagnosis of lymphatic
ysfunction include delayed, asymmetric or absent visual-
zation of regional lymph nodes, asymmetric visualization of
ymphatic channels, collateral lymphatic channels, inter-
upted vascular structures, and visualization of the lymph
odes of the deep lymphatic system. The presence of ldermal back-flow” is abnormal, and is generally interpreted
o represent the extravasation of lymph from the vasculature
nto the interstitium as a consequence of lymphatic venous
ypertension.
Beyond lymphoscintigraphy, clinically relevant imaging
odalities include magnetic resonance imaging and com-
uterized axial tomography. These imaging techniques per-
it objective documentation of the structural changes oc-
asioned by the presence of lymphedema (38), inasmuch as
he presence of edema within the epifascial plane, along
ith cutaneous thickening, is characteristic of a lymphatic
ause for edema. Magnetic resonance imaging has comple-
entary utility (39). Recent advances in the magnetic
esonance approach have vastly facilitated the anatomic and
unctional visualization of lymphatic vascular anomalies, in
oth nonenhanced (40) and contrast-enhanced (41) appli-
ations. The latter approach has been investigated directly
or the evaluation of lymphedema of the limb.
Bioelectric impedance analysis is an emerging diagnos-
ic technique for the clinical evaluation of lymphatic
dema. The technique facilitates the noninvasive quanti-
cation of extracellular fluid in the extremities; given its
ensitivity and reproducibility, it is likely to find increas-
ng application in the early detection and management of
Figure 1 A Patient With Severe, Chronic
Lymphedema of Both Lower Extremities
The accentuation of the normal skin folds should be noted. In
addition to edema, there is profound thickening of the cutaneous structures.ymphatic edema (42).
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September 2, 2008:799–806 Lymphatic Vascular Diseasereatment of Lymphatic Vascular Diseases
he state-of-the-art therapeutic approach to lymphatic
dema relies upon physiotherapeutic techniques. Complex
econgestive physiotherapy (CDPT) is an empirically de-
ived, effective, multicomponent technique designed to re-
uce limb volume and maintain the health of the skin and
upporting structures. There is some evidence that this
pproach stimulates lymphatic transport and facilitates the
ispersal of retained interstitial proteins (36).
CDPT relies heavily upon an empirically derived,
ymphatic-specific massage technique termed manual lym-
hatic drainage (MLD) (43). A mild degree of manually
elivered tissue compression serves to enhance filling of the
utaneous initial lymphatics and augments dilation and
ontractility of the lymphatic conduits. MLD is believed to
acilitate the recruitment of watershed pathways for lymph
ow through its attempts to stimulate the edema-free zones
f the trunk and uninvolved extremities. It is also postulated
hat the technique enhances the development of accessory
ymph collectors.
In addition to MLD, the CDPT approach integrates skin
are, exercise, and the use of externally applied compression.
n the initial management of a previously untreated patient,
his compression takes the form of repetitively applied short
tretch bandaging, in order to create a multilayer compart-
ent that, during muscular activity, augments the physio-
ogical mechanisms that regulate lymphatic contractility and
ow (44). In addition, during active tissue compression,
here is a reduction in the abnormally increased ultrafiltra-
ion which, in turn, leads to improved fluid reabsorption.
ventually, with repetitive physical interventions and ban-
age applications, edema volume will achieve its nadir; at
his point, maintenance of the therapeutic benefits will
equire the use of fitted elastic garments for use during
onrecumbency. In smaller numbers of patients, nocturnal
ompression may also be required. Relatively inelastic
leeves and underwear that transmit high-grade compres-
ion (40 to 80 mm Hg) will prevent reaccumulation of fluid
fter successful CDPT. Garments must be fitted properly
nd replaced every 3 to 6 months.
The therapeutic efficacy of CDPT has been validated.
hen examined in a series of patients with either upper or
ower extremity lymphedema, with an average follow-up of
months, average volume reductions of 59% and 68% were
bserved in the upper and lower limbs, respectively (45);
aintenance self-management techniques are effective in
ustaining the majority of this benefit in compliant patients
45–47).
While CDPT affords benefit to the majority of patients
ith lymphedema, the fact that the interventions are labor-
ntensive, time-consuming, and expensive cannot be re-
uted. Furthermore, the potentially uncomfortable and very
isible impact of the requisite garments may erode the
atients’ quality of life. Furthermore, the interventions are
ot uniformly successful. Most patients achieve adequate idema control, but some will require the input of
djunctive devices (43). Notably, intermittent pneumatic
ompression has been shown to augment the decompres-
ive effects of standard therapies, especially in the context
f cancer-associated lymphedema (48). More recently, an
daption of intermittent pneumatic compression has been
ntroduced that, while delivering minimal, phasic exter-
al compression, endeavors to simulate the effects of
LD; this device, when used adjunctively in the main-
enance phase of therapy, appears to augment the bene-
cial impact of the standard modalities of CDPT. Other
djunctive approaches, including the external application
f hyperthermia (49,50) and low-level laser (51,52),
ontinue to be investigated. Surgical approaches to im-
rove lymphatic flow through vascular reanastomosis
ave been, in large part, unsuccessful (53), but over the
ast 15 years there has been consistent evidence for the
eneficial effect, in the appropriately selected patient, of
ontrolled liposuction when coupled with the requisite,
ustained aggressive post-operative compression (54,55);
his approach will restore and maintain normal limb
olume and contour after the markedly enlarged subcu-
aneous adipose layer and hyperplastic soft tissues, both
nexorable consequences of long-standing lymphedema
8), have been removed in a controlled surgical interven-
ion. Surgical intervention may be warranted in lym-
hangiomatosis, and debulking surgery is required
or KTS.
The application of pharmacological therapies has been
otably absent from the management strategies for lym-
hatic vascular insufficiency states. In general, drug-based
pproaches have been controversial, at best. Coumarin has
een reported to provide benefit in lymphedema (56), but
he salutary effects of the drug are not universally acknowl-
dged, and the poor study design of most of the trials limits
nterpretability (57). The therapeutic benefit, if present, has
een theoretically ascribed to its effect on cutaneous mac-
ophages and, thereby, on local proteolysis. This drug also
timulates other cellular elements of the immune system and
ay promote protein reabsorption. Despite some encour-
ging early trials, this agent must still be considered to have
n experimental role, which may be further hampered by its
apacity to confer hepatotoxicity when given systemically
57). A therapeutic role for selenium, flavonoids, and other
ntioxidants has been proposed (58), but little supporting
vidence exists.
Diuretic therapy has little, if any, role in the management
f isolated lymphatic vascular insufficiency, since the patho-
enesis of the edema relies upon the elevated interstitial
ncotic pressures conferred by macromolecules, rather than
pon inappropriate retention of water and electrolytes.
owever, in cases where hydrostatic pressure is also ele-
ated, such as the post-phlebitic syndrome with secondary
ypertension, low-dose thiazide-induced diuresis may play a
eneficial complementary role to the primary therapeutic
ntervention, which is compression.
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Lymphatic Vascular Disease September 2, 2008:799–806Dietary therapy plays little role in lymphedema. Of note,
owever, is the fact that, in selected settings, restriction of
ietary fat, when coupled with supplementation of medium
hain triglycerides, can markedly reduce the requirement for
isceral lymph production; this approach is particularly
seful in protein-losing enteropathy and in cases where
hylous effusions exist.
Within the spectrum of the lymphatic vascular disease,
here are circumstances that mandate specific therapeutic
ntervention. For patients with lymphorrhea (59) or large,
ecurrent chylous effusions, the systemic administration of
omatostatin or its synthetic analog, octreotide, has been
hown to be therapeutically advantageous (60). This ap-
roach may be particularly useful when there is evidence of
horacic duct or superior vena caval obstruction. The mech-
nisms by which somatostatin and octreotide inhibit tho-
acic duct flow are not well known. Octreotide may act
irectly on somatostatin receptors in the splanchnic circu-
ation to reduce lymph fluid production. In addition, tho-
acic duct lymphatic flow depends on splanchnic vascular
one and gastric motility. Because octreotide can decrease
he volume of gastric, pancreatic, and biliary secretions, the
olume and protein content of fluid within the thoracic duct
ay reduce concomitantly.
For patients with protein-losing enteropathy, intravenous
lbumin replacement (61), high-dose corticosteroid therapy
62), or small bowel resection may be beneficial. In patients
ith enteropathy as a consequence of congenital heart
isease, recent heparin administration may reduce leakage of
rotein into intestinal lumen (61).
Patients with LAM have unique therapeutic strategies.
reatment is often focused on the reduction or prevention
f pneumothorax through pleurodesis and pleurectomy (63).
mbolization of angiomyolipomas is performed when nec-
ssary. Progesterone may slow the progression of LAM, but
as a large potential for side effects (64,65). Current
esearch efforts are focused on rapamycin as a useful agent
irect against the disease-associated angiomyolipomas (35).
he Future Promise
f Molecular Treatment Strategies
he recently acquired insights into the molecular regulation
f lymphatic vascular development have fostered sustained
nterest in the therapeutic potential to modulate post-natal
ymphatic vessel growth and remodeling (1,66). A suitable
rojected target for such therapeutic interventions might be
he activation of VEGFR-3 by the secreted growth factor
ascular endothelial growth factor (VEGF)-C (67). One of
he defined roles of VEGF-C is to trigger a signaling
ascade through VEGFR-3 binding that, in turn, allows for
timulation of lymphangiogenesis (68). A similar phenom-
non has been demonstrated with VEGF-D (67). Binding
f VEGF-C to VEGFR-3 has also been thought to mediate
he growth and viability of lymphatic endothelial cells (69).A murine model of Milroy’s disease has been utilized to
llustrate the potential for gene therapy in lymphedema. In-
uction of functional lymphatic vessels in these mice has been
bserved after overexpression of VEGFR-3 ligands, support-
ng the sufficiency of VEGF-C/D signaling to promote ther-
peutic lymphangiogenesis (70). Acquired lymphedema has
lso been investigated in animal model systems: ablation of the
ymphatic vasculature results in lymphedema that is amenable
o therapeutic lymphangiogenesis. Both direct administration
f recombinant VEGF-C and plasma-mediated gene therapy
roduce a demonstrable reversal of the pathology of lymph-
dema (71–73). In addition to the ligands for the VEGFR-3
eceptor, VEGF-A (74), fibroblast growth factor-2 (74), and
epatocyte growth factor (75) may each play a significant role
n the future molecular therapeutics of lymphedema. In the
uture, specifically engineered molecular therapeutics may be
esigned to facilitate the controlled regrowth of damaged,
ysfunctional, or obliterated lymphatic vasculature in order to
ircumvent or mitigate the vascular insufficiency that leads to
dema and tissue destruction (76).
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